Myeloid and Mesenchymal Stem Cell Therapies for Solid Organ Transplant Tolerance.
Myeloid and Mesenchymal Stem Cell Therapies for Solid Organ Transplant Tolerance.
复制标题
DOI：
10.1097/tp.0000000000003765
复制
发表时间：
2021-12-01
期刊：
影响因子：
6.2
通讯作者：
Rogers NM
中科院分区：
文献类型：
--
作者：
Li J;Thomson AW;Rogers NM
Transplantation is now performed globally as a routine procedure. However, the increased demand for donor organs and consequent expansion of donor criteria has created an imperative to maximize the quality of these gains. The goal is to balance preservation of allograft function against patient quality-of-life, despite exposure to long-term immunosuppression. Elimination of immunosuppressive therapy to avoid drug toxicity, with concurrent acceptance of the allograft – so-called operational tolerance – has proven elusive. The lack of recent advances in immunomodulatory drug development, together with advances in immunotherapy in oncology, has prompted interest in cell-based therapies to control the alloimmune response. Extensive experimental work in animals has characterized regulatory immune cell populations that can induce and maintain tolerance, demonstrating that their adoptive transfer can promote donor-specific tolerance. An extension of this large body of work has resulted in protocols for manufacture, as well as early-phase safety and feasibility trials for many regulatory cell types. Despite the excitement generated by early clinical trials in autoimmune diseases and organ transplantation, there is as yet no clinically validated, approved regulatory cell therapy for transplantation. In this review, we summarize recent advances in this field, with a focus on myeloid and mesenchymal cell therapies, including current understanding of the mechanisms of action of regulatory immune cells, and clinical trials in organ transplantation using these cells as therapeutics.
影响因子：
3.7
作者：
Sun G;Shan J;Li Y;Zhou Y;Guo Y;Wu W;Yang T;Xia M;Feng L
通讯作者：
Feng L